Viral Vectors & Plasmid DNA Manufacturing Market Size to Worth Around USD 10.6 Bn by 2030
The global Viral Vectors & Plasmid DNA Manufacturing market size is expected to reach USD 10.6 billion by 2030, registering a CAGR of 20.8% over the forecast period 2021 – 2030.
Download Exclusive Sample of Report@ https://www.visionresearchreports.com/report/sample/38494
Growth Factors
Advent of advanced therapies including gene therapy that employs the use of various viral and non-viral vectors has paved a way for the treatment of several heritable and acquired diseases that previously lacked effective treatment modalities. Post the approval of Novartis’s Zolgensma, drug developers have begun considering these new areas of treatment as a sustainable business model. Thus, the speculated accelerating investment is expected to drive the growth.
Current production methods for viral vectors are considered tedious, as they are only applicable for scale-out but not for scale-up. Development of a proprietary CAP-GT technology-based cell suspension system by CEVEC Pharmaceuticals GmbH has effectively addressed the challenge of scaling-up by allowing easy handling and improved efficiency of cells.
Report Coverage
| Report Scope | Details |
| Market Size | USD 10.6 Billion by 2030 |
| Growth Rate | CAGR of 20.8% From 2021 to 2030 |
| Base Year | 2020 |
| Historic Data | 2017 to 2020 |
| Forecast Period | 2021 to 2030 |
| Segments Covered | Type, Workflow, Application, End-use, Disease |
| Regional Scope | North America, Europe, Asia Pacific, Latin America, Middle East & Africa |
| Companies Mentioned | Novasep, Aldevron, MerckWaismanBiomanufacturing, Creative Biogene,The Cell and Gene Therapy Catapult,Cobra Biologics,uniQure N.V.,Addgene,FUJIFILM Holdings Corporation,Oxford Biomedicaplc,Takara Bio Inc. |
Vector Type Insights
Targeted delivery, efficient transduction, and controlled gene expression are some of the key factors taken into consideration while manufacturing vectors. Viral vectors are increasingly being employed in the ongoing clinical trials owing to their efficiency in gene delivery. Out of all the viral vectors, adenovirus and retrovirus are most commonly used within research settings across the globe.
Workflow Insights
The growing necessity of vectors to meet the rising demand for robust therapies has pronounced the need for optimization of upstream processing and downstream processing workflows. Virus preparation methods at small-scale involve steps that are difficult to scale-up and are often considered tedious.
Aplication Insights
Antisense and RNAi, gene therapies are the leading application of viral and plasmid vector in terms of revenue share. Small interfering RNAs (siRNAs) are currently considered significant tools for post-transcriptional gene silencing during a genetic analysis of cells. The presence of pipeline products is expected to boost growth of this segment over the forecast period.
Furthermore, the emergence of retroviral vectors as a viable solution for addressing the low transfection efficiency-related drawbacks of plasmid-based systems is one of the key development in antisense and RNAi production. Growing usage of AAV vectors for delivery of siRNA in mammalian cells is driving revenue in this segment.
End-use Insights
Pharmaceutical and biotechnology companies accounted for the largest share in the viral vectors & plasmid DNA manufacturing market in 2019. This can be attributed to the continuous introduction of advanced therapies coupled with a subsequent increase in the number of gene therapy-based discovery programs by companies. The number of biotech companies employing vectors for therapeutics production continues to increase over the period of time.
Disease Insights
Viral vectors are being studied for both preventive and therapeutic applications in cancer. Viral vector-based immunization with anticancer antigens or delivery of toxic or anticancer genes are some key areas or research that have shown steady progress in recent times. Furthermore, recent approvals of lentiviral vector-based CAR-T cell therapies for Acute Lymphoblastic Leukemia (ALL) and large B cell lymphoma have attracted considerable attention from key end-users. This has resulted in significant proliferation in the cancer-based pipeline projects on advanced therapies.
Regional Insights
Recent FDA approval of advanced therapies such as Kymriah (tisagenlecleucel) and Yescarta is one of the key factors contributing to the largest revenue share of the U.S. market. These approvals have resulted in an increase in the number of companies operating in this area in U.S. In 2020, an estimated 391 gene therapy companies were operating in the U.S. By September 2019, around 100 more companies including big pharma companies entered the market.
Key Players
- Novasep
- Aldevron
- MerckWaismanBiomanufacturing
- Creative Biogene
- The Cell and Gene Therapy Catapult
- Cobra Biologics
- uniQure N.V.
- Addgene
- FUJIFILM Holdings Corporation
- Oxford Biomedicaplc
- Takara Bio Inc.
Market Segmentation
By Vector Type Outlook
- Adenovirus
- Retrovirus
- Plasmid DNA
- AAV
- Lentivirus
- Others
By Workflow Outlook
- Upstream Processing
- Vector Amplification & Expansion
- Vector Recovery/Harvesting
- Downstream Processing
- Purification
- Fill-finish
By Application Outlook
- Antisense & RNAi
- Gene Therapy
- Cell Therapy
- Vaccinology
By End-use Outlook
- Pharmaceutical and Biopharmaceutical Companies
- Research Institutes
By Disease Outlook
- Cancer
- Genetic Disorders
- Infectious Diseases
- Others
By Regional Outlook
- North America
- U.S.
- Canada
- Europe
- Germany
- U.K.
- Asia Pacific
- China
- Japan
- Latin America
- Brazil
- Middle East & Africa
- South Africa
Buy this Research Report study@ https://www.visionresearchreports.com/report/cart/38494
Reasons to Purchase this Report:
– Market segmentation analysis including qualitative and quantitative research incorporating the impact of economic and policy aspects
– Regional and country level analysis integrating the demand and supply forces that are influencing the growth of the market.
– Market value USD Million and volume Units Million data for each segment and sub-segment
– Competitive landscape involving the market share of major players, along with the new projects and strategies adopted by players in the past five years
– Comprehensive company profiles covering the product offerings, key financial information, recent developments, SWOT analysis, and strategies employed by the major market players
Table of Contents
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. Market Dynamics Analysis and Trends
5.1. Market Dynamics
5.1.1. Market Drivers
5.1.2. Market Restraints
5.1.3. Market Opportunities
5.2. Porter’s Five Forces Analysis
5.2.1. Bargaining power of suppliers
5.2.2. Bargaining power of buyers
5.2.3. Threat of substitute
5.2.4. Threat of new entrants
5.2.5. Degree of competition
Chapter 6. Competitive Landscape
6.1.1. Company Market Share/Positioning Analysis
6.1.2. Key Strategies Adopted by Players
6.1.3. Vendor Landscape
6.1.3.1. List of Suppliers
6.1.3.2. List of Buyers
Chapter 7. Global Viral Vectors & Plasmid DNA Manufacturing Market, By Vector Type
7.1. Viral Vectors & Plasmid DNA Manufacturing Market, by Vector Type, 2021-2030
7.1.1. Adenovirus
7.1.1.1. Market Revenue and Forecast (2017-2030)
7.1.2. Plasmid DNA
7.1.2.1. Market Revenue and Forecast (2017-2030)
7.1.3. Lentivirus
7.1.3.1. Market Revenue and Forecast (2017-2030)
7.1.4. Retrovirus
7.1.4.1. Market Revenue and Forecast (2017-2030)
7.1.5. AAV
7.1.5.1. Market Revenue and Forecast (2017-2030)
7.1.6. Others
7.1.6.1. Market Revenue and Forecast (2017-2030)
Chapter 8. Global Viral Vectors & Plasmid DNA Manufacturing Market, By Application Type
8.1. Viral Vectors & Plasmid DNA Manufacturing Market, by Application Type, 2021-2030
8.1.1. Gene Therapy
8.1.1.1. Market Revenue and Forecast (2017-2030)
8.1.2. Antisense &RNAi
8.1.2.1. Market Revenue and Forecast (2017-2030)
8.1.3. Cell Therapy
8.1.3.1. Market Revenue and Forecast (2017-2030)
8.1.4. Vaccinology
8.1.4.1. Market Revenue and Forecast (2017-2030)
Chapter 9. Global Viral Vectors & Plasmid DNA Manufacturing Market, By Workflow Type
9.1. Viral Vectors & Plasmid DNA Manufacturing Market, by Workflow Type, 2021-2030
9.1.1. Upstream Processing (Vector Recovery/Harvesting, Vector Amplification & Expansion)
9.1.1.1. Market Revenue and Forecast (2017-2030)
9.1.2. Downstream Processing (Fill-finish, Purification)
9.1.2.1. Market Revenue and Forecast (2017-2030)
Chapter 10. Global Viral Vectors & Plasmid DNA Manufacturing Market, By End-User Type
10.1. Viral Vectors & Plasmid DNA Manufacturing Market, by End-User Type, 2021-2030
10.1.1. Biopharmaceutical and Pharmaceutical Companies
10.1.1.1. Market Revenue and Forecast (2017-2030)
10.1.2. Research Institutes
10.1.2.1. Market Revenue and Forecast (2017-2030)
Chapter 11. Global Viral Vectors & Plasmid DNA Manufacturing Market, By Disease
11.1. Viral Vectors & Plasmid DNA Manufacturing Market, by Disease, 2021-2030
11.1.1. Genetic Disorders
11.1.1.1. Market Revenue and Forecast (2017-2030)
11.1.2. Cancer
11.1.2.1. Market Revenue and Forecast (2017-2030)
11.1.3. Infectious Diseases
11.1.3.1. Market Revenue and Forecast (2017-2030)
11.1.4. Others
11.1.4.1. Market Revenue and Forecast (2017-2030)
Chapter 12. Global Viral Vectors & Plasmid DNA Manufacturing Market, Regional Estimates and Trend Forecast
12.1. North America
12.1.1. Market Revenue and Forecast, by Vector (2017-2030)
12.1.2. Market Revenue and Forecast, by Application (2017-2030)
12.1.3. Market Revenue and Forecast, by Workflow (2017-2030)
12.1.4. Market Revenue and Forecast, by End-User (2017-2030)
12.1.5. Market Revenue and Forecast, by Disease (2017-2030)
12.1.6. U.S.
12.1.6.1. Market Revenue and Forecast, by Vector (2017-2030)
12.1.6.2. Market Revenue and Forecast, by Application (2017-2030)
12.1.6.3. Market Revenue and Forecast, by Workflow (2017-2030)
12.1.6.4. Market Revenue and Forecast, by End-User (2017-2030)
12.1.7. Market Revenue and Forecast, by Disease (2017-2030)
12.1.8. Rest of North America
12.1.8.1. Market Revenue and Forecast, by Vector (2017-2030)
12.1.8.2. Market Revenue and Forecast, by Application (2017-2030)
12.1.8.3. Market Revenue and Forecast, by Workflow (2017-2030)
12.1.8.4. Market Revenue and Forecast, by End-User (2017-2030)
12.1.9. Market Revenue and Forecast, by Disease (2017-2030)
12.2. Europe
12.2.1. Market Revenue and Forecast, by Vector (2017-2030)
12.2.2. Market Revenue and Forecast, by Application (2017-2030)
12.2.3. Market Revenue and Forecast, by Workflow (2017-2030)
12.2.4. Market Revenue and Forecast, by End-User (2017-2030)
12.2.5. Market Revenue and Forecast, by Disease (2017-2030)
12.2.6. UK
12.2.6.1. Market Revenue and Forecast, by Vector (2017-2030)
12.2.6.2. Market Revenue and Forecast, by Application (2017-2030)
12.2.6.3. Market Revenue and Forecast, by Workflow (2017-2030)
12.2.7. Market Revenue and Forecast, by End-User (2017-2030)
12.2.8. Market Revenue and Forecast, by Disease (2017-2030)
12.2.8.1. Market Revenue and Forecast, by Raw Material (2017-2030)
12.2.9. Germany
12.2.9.1. Market Revenue and Forecast, by Vector (2017-2030)
12.2.9.2. Market Revenue and Forecast, by Application (2017-2030)
12.2.9.3. Market Revenue and Forecast, by Workflow (2017-2030)
12.2.10. Market Revenue and Forecast, by End-User (2017-2030)
12.2.11. Market Revenue and Forecast, by Disease (2017-2030)
12.2.12. France
12.2.12.1. Market Revenue and Forecast, by Vector (2017-2030)
12.2.12.2. Market Revenue and Forecast, by Application (2017-2030)
12.2.12.3. Market Revenue and Forecast, by Workflow (2017-2030)
12.2.12.4. Market Revenue and Forecast, by End-User (2017-2030)
12.2.13. Market Revenue and Forecast, by Disease (2017-2030)
12.2.14. Rest of Europe
12.2.14.1. Market Revenue and Forecast, by Vector (2017-2030)
12.2.14.2. Market Revenue and Forecast, by Application (2017-2030)
12.2.14.3. Market Revenue and Forecast, by Workflow (2017-2030)
12.2.14.4. Market Revenue and Forecast, by End-User (2017-2030)
12.2.15. Market Revenue and Forecast, by Disease (2017-2030)
12.3. APAC
12.3.1. Market Revenue and Forecast, by Vector (2017-2030)
12.3.2. Market Revenue and Forecast, by Application (2017-2030)
12.3.3. Market Revenue and Forecast, by Workflow (2017-2030)
12.3.4. Market Revenue and Forecast, by End-User (2017-2030)
12.3.5. Market Revenue and Forecast, by Disease (2017-2030)
12.3.6. India
12.3.6.1. Market Revenue and Forecast, by Vector (2017-2030)
12.3.6.2. Market Revenue and Forecast, by Application (2017-2030)
12.3.6.3. Market Revenue and Forecast, by Workflow (2017-2030)
12.3.6.4. Market Revenue and Forecast, by End-User (2017-2030)
12.3.7. Market Revenue and Forecast, by Disease (2017-2030)
12.3.8. China
12.3.8.1. Market Revenue and Forecast, by Vector (2017-2030)
12.3.8.2. Market Revenue and Forecast, by Application (2017-2030)
12.3.8.3. Market Revenue and Forecast, by Workflow (2017-2030)
12.3.8.4. Market Revenue and Forecast, by End-User (2017-2030)
12.3.9. Market Revenue and Forecast, by Disease (2017-2030)
12.3.10. Japan
12.3.10.1. Market Revenue and Forecast, by Vector (2017-2030)
12.3.10.2. Market Revenue and Forecast, by Application (2017-2030)
12.3.10.3. Market Revenue and Forecast, by Workflow (2017-2030)
12.3.10.4. Market Revenue and Forecast, by End-User (2017-2030)
12.3.10.5. Market Revenue and Forecast, by Disease (2017-2030)
12.3.11. Rest of APAC
12.3.11.1. Market Revenue and Forecast, by Vector (2017-2030)
12.3.11.2. Market Revenue and Forecast, by Application (2017-2030)
12.3.11.3. Market Revenue and Forecast, by Workflow (2017-2030)
12.3.11.4. Market Revenue and Forecast, by End-User (2017-2030)
12.3.11.5. Market Revenue and Forecast, by Disease (2017-2030)
12.4. MEA
12.4.1. Market Revenue and Forecast, by Vector (2017-2030)
12.4.2. Market Revenue and Forecast, by Application (2017-2030)
12.4.3. Market Revenue and Forecast, by Workflow (2017-2030)
12.4.4. Market Revenue and Forecast, by End-User (2017-2030)
12.4.5. Market Revenue and Forecast, by Disease (2017-2030)
12.4.6. GCC
12.4.6.1. Market Revenue and Forecast, by Vector (2017-2030)
12.4.6.2. Market Revenue and Forecast, by Application (2017-2030)
12.4.6.3. Market Revenue and Forecast, by Workflow (2017-2030)
12.4.6.4. Market Revenue and Forecast, by End-User (2017-2030)
12.4.7. Market Revenue and Forecast, by Disease (2017-2030)
12.4.8. North Africa
12.4.8.1. Market Revenue and Forecast, by Vector (2017-2030)
12.4.8.2. Market Revenue and Forecast, by Application (2017-2030)
12.4.8.3. Market Revenue and Forecast, by Workflow (2017-2030)
12.4.8.4. Market Revenue and Forecast, by End-User (2017-2030)
12.4.9. Market Revenue and Forecast, by Disease (2017-2030)
12.4.10. South Africa
12.4.10.1. Market Revenue and Forecast, by Vector (2017-2030)
12.4.10.2. Market Revenue and Forecast, by Application (2017-2030)
12.4.10.3. Market Revenue and Forecast, by Workflow (2017-2030)
12.4.10.4. Market Revenue and Forecast, by End-User (2017-2030)
12.4.10.5. Market Revenue and Forecast, by Disease (2017-2030)
12.4.11. Rest of MEA
12.4.11.1. Market Revenue and Forecast, by Vector (2017-2030)
12.4.11.2. Market Revenue and Forecast, by Application (2017-2030)
12.4.11.3. Market Revenue and Forecast, by Workflow (2017-2030)
12.4.11.4. Market Revenue and Forecast, by End-User (2017-2030)
12.4.11.5. Market Revenue and Forecast, by Disease (2017-2030)
12.5. Latin America
12.5.1. Market Revenue and Forecast, by Vector (2017-2030)
12.5.2. Market Revenue and Forecast, by Application (2017-2030)
12.5.3. Market Revenue and Forecast, by Workflow (2017-2030)
12.5.4. Market Revenue and Forecast, by End-User (2017-2030)
12.5.5. Market Revenue and Forecast, by Disease (2017-2030)
12.5.6. Brazil
12.5.6.1. Market Revenue and Forecast, by Vector (2017-2030)
12.5.6.2. Market Revenue and Forecast, by Application (2017-2030)
12.5.6.3. Market Revenue and Forecast, by Workflow (2017-2030)
12.5.6.4. Market Revenue and Forecast, by End-User (2017-2030)
12.5.7. Market Revenue and Forecast, by Disease (2017-2030)
12.5.8. Rest of LATAM
12.5.8.1. Market Revenue and Forecast, by Vector (2017-2030)
12.5.8.2. Market Revenue and Forecast, by Application (2017-2030)
12.5.8.3. Market Revenue and Forecast, by Workflow (2017-2030)
12.5.8.4. Market Revenue and Forecast, by End-User (2017-2030)
12.5.8.5. Market Revenue and Forecast, by Disease (2017-2030)
Chapter 13. Company Profiles
13.1. Novasep
13.1.1. Company Overview
13.1.2. Product Offerings
13.1.3. Financial Performance
13.1.4. Recent Initiatives
13.2. Aldevron
13.2.1. Company Overview
13.2.2. Product Offerings
13.2.3. Financial Performance
13.2.4. Recent Initiatives
13.3. Merck Waisman Biomanufacturing
13.3.1. Company Overview
13.3.2. Product Offerings
13.3.3. Financial Performance
13.3.4. Recent Initiatives
13.4. Creative Biogene
13.4.1. Company Overview
13.4.2. Product Offerings
13.4.3. Financial Performance
13.4.4. Recent Initiatives
13.5. The Cell and Gene Therapy Catapult
13.5.1. Company Overview
13.5.2. Product Offerings
13.5.3. Financial Performance
13.5.4. Recent Initiatives
13.6. Cobra Biologics
13.6.1. Company Overview
13.6.2. Product Offerings
13.6.3. Financial Performance
13.6.4. Recent Initiatives
13.7. uniQure N.V.
13.7.1. Company Overview
13.7.2. Product Offerings
13.7.3. Financial Performance
13.7.4. Recent Initiatives
13.8. Addgene
13.8.1. Company Overview
13.8.2. Product Offerings
13.8.3. Financial Performance
13.8.4. Recent Initiatives
13.9. FUJIFILM Holdings Corporation
13.9.1. Company Overview
13.9.2. Product Offerings
13.9.3. Financial Performance
13.9.4. Recent Initiatives
13.10. Oxford Biomedicaplc
13.10.1. Company Overview
13.10.2. Product Offerings
13.10.3. Financial Performance
13.10.4. Recent Initiatives
13.11. Takara Bio Inc.
13.11.1. Company Overview
13.11.2. Product Offerings
13.11.3. Financial Performance
13.11.4. Recent Initiatives
Chapter 14. Research Methodology
14.1. Primary Research
14.2. Secondary Research
14.3. Assumptions
Chapter 15. Appendix
15.1. About Us
15.2. Glossary of Terms
Buy this Research Report study@ https://www.visionresearchreports.com/report/cart/38494
Contact Us:
Vision Research Reports
Call: +1 9197 992 333
